Ed Hodgkin

Ed Hodgkin – BIA Chairman-designate

I was delighted to see the Chancellor of the Exchequer announce in his Spending Review that the Technology Strategy Board would receive an additional £185 million to support innovation, including Catapult Centres and the Biomedical Catalyst. George Freeman, MP, the government’s Life Sciences Advisor, told me that the BIA’s campaign, in particular the letters from our members, had played a critical part in the Treasury’s decision. I would like to thank all of you that contributed to this.

The exact funding split has not yet been announced and the BIA will work with all stakeholders to ensure timely and accurate communication when it is available. On Tuesday this week I will be meeting with the TSB to understand the details of how this funding will be scheduled and allocated.

Internally at the BIA, I am pleased that our Board has elected Ed Hodgkin as its new Chairman from October. Ed has been a BIA Board member since 2010 and I am sure many of you will know him from his current role at Syncona Partners or previously at Biotica Technology. I welcome Ed to his new role and look forward to working even more closely with him, building on our excellent relationship established through his current role on the BIA Executive and Board.

Today (Monday) the BIA has announced a formal collaboration with Bionow, BioPartner UK and One Nucleus to support the UK life science sector. We will jointly develop a life science manifesto for the 2015-20 parliament and will run a series of workshops and webinars to help UK bioscience companies grow their businesses faster. I am looking forward to working with Geoff, Lin and Harriet and their teams, and we will be in touch soon with more details.

Last week we launched our UK Bioscience Forum with London Mayor Boris Johnson and BIO CEO Jim Greenwood confirmed as our keynote speakers. Book today to benefit from the early bird registration rate.